Wolfe Research initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $75 price target Revolution is “emerging as the clear leader in pancreatic cancer” with darxonrasib, the analyst tells investors. First-in-class is important in this space and the firm’s analysis suggests the key second-line Phase 3 readout will hit next year, the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines’ Q3 2025 Earnings Call Highlights
- Erasca price target raised to $6 from $4 at Stifel
- Revolution Medicines: Buy Rating Reaffirmed Amid Strategic Developments and Increased Price Target
- JPMorgan ups Revolution Medicines target, adds to Analyst Focus List
- Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright